Compare
Inhibikase Therapeutics, Inc. vs Vaxart, Inc. vs Editas Medicine, Inc. vs Caribou Biosciences, Inc.
| Latest fiscal year | Inhibikase Therapeutics, Inc. IKT | Vaxart, Inc. VXRT | Editas Medicine, Inc. EDIT | Caribou Biosciences, Inc. CRBU |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $237.26M | $40.52M | $11.16M |
| Revenue growth (YoY) | n/a | +726.7% | +25.4% | +11.7% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | 7.6% | -394.9% | n/m |
| Net margin | n/a | 6.9% | -395.0% | n/m |
| Net income | -$48.26M | $16.33M | -$160.06M | -$148.12M |
| EPS (Diluted) | -$0.49 | $0.07 | -$1.80 | -$1.59 |
| Operating cash flow | -$27.79M | $7.71M | -$165.24M | -$110.99M |
| Free cash flow | -$27.80M | $7.57M | -$165.85M | -$112.35M |
| Cash & equivalents | $178.80M | n/a | $146.65M | $12.36M |
| Total assets | $181.20M | $186.08M | $186.53M | $175.37M |
| Total liabilities | $8.30M | $98.28M | $159.25M | $53.19M |
| Shareholders' equity | $172.90M | $87.80M | $27.29M | $122.17M |
| Return on year-end equity | -27.9% | 18.6% | -586.6% | -121.2% |
| Shares outstanding | 131.69M | 240.49M | 97.87M | 95.14M |
Revenue, most recent five fiscal years
| Fiscal year | Inhibikase Therapeutics, Inc. | Vaxart, Inc. | Editas Medicine, Inc. | Caribou Biosciences, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2024-12-31 | $237.26M Ended 2025-12-31 | $40.52M Ended 2025-12-31 | $11.16M Ended 2025-12-31 |
| 1 year earlier | $260.5K Ended 2023-12-31 | $28.70M Ended 2024-12-31 | $32.31M Ended 2024-12-31 | $9.99M Ended 2024-12-31 |
| 2 years earlier | $123.4K Ended 2022-12-31 | $7.38M Ended 2023-12-31 | $78.12M Ended 2023-12-31 | $34.48M Ended 2023-12-31 |
| 3 years earlier | $3.10M Ended 2021-12-31 | $107.0K Ended 2022-12-31 | $19.71M Ended 2022-12-31 | $13.85M Ended 2022-12-31 |
| 4 years earlier | $698.5K Ended 2020-12-31 | $892.0K Ended 2021-12-31 | $25.54M Ended 2021-12-31 | $9.60M Ended 2021-12-31 |